Decoy Therapeutics Inc.
DCOY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001615219
No open-market purchases or sales by Decoy Therapeutics Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $31.0K in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Decoy Therapeutics Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −5 vs. Q2 2022
- Shares held
- 3.45M
- −655.0K (−16.0%) vs. Q2 2022
- Total value
- $671.0K
- −$188.0K (−21.9%) vs. Q2 2022
- New holders
- 0
- 3 more added
- Sold out
- 5
- 9 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DCOY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 4 | $31.0K |
| Q1 2026 | 4 | $10.5K |
| Q4 2025 | 9 | $51.4K |
| Q3 2025 | 5 | $1.98K |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 13 | $101.9K |
| Q4 2023 | 16 | $169.8K |
| Q3 2023 | 14 | $226.8K |
| Q2 2023 | 14 | $321.5K |
| Q1 2023 | 11 | $186.0K |
| Q4 2022 | 9 | $110.9K |
| Q3 2022 | 22 | $671.0K |
| Q2 2022 | 27 | $859.0K |
| Q1 2022 | 28 | $1.45M |
| Q4 2021 | 28 | $2.63M |
| Q3 2021 | 27 | $6.84M |
| Q2 2021 | 34 | $10.7M |
| Q1 2021 | 34 | $22.8M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Decoy Therapeutics Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,353,373 | $264.0K | 0.00% | −231,647−14.6% | Reduced |
| Renaissance Technologies LLC | 634,261 | $124.0K | 0.00% | +96,200+17.9% | Added |
| Geode Capital Management, LLC | 413,135 | $80.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 310,000 | $60.0K | 0.00% | −16,200−5.0% | Reduced |
| State Street Corp | 142,552 | $28.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 115,683 | $23.0K | 0.00% | −176,217−60.4% | Reduced |
| X-Square Capital, LLC | 89,000 | $17.0K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 65,022 | $13.0K | 0.00% | 00.0% | Unchanged |
| Horizon Kinetics Asset Management LLC | 60,000 | $12.0K | 0.00% | +20,000+50.0% | Added |
| UBS Group AG | 40,848 | $8.00K | 0.00% | −1,437−3.4% | Reduced |
| Wetherby Asset Management Inc | 39,746 | $8.00K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 35,265 | $7.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 34,700 | $6.00K | 0.00% | −40.0% | Reduced |
| ERn Financial, LLC | 32,050 | $6.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 24,089 | $5.00K | 0.00% | −55,123−69.6% | Reduced |
| Cambridge Investment Research Advisors, Inc. | 21,289 | $4.00K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 12,187 | $2.00K | 0.00% | −3,308−21.3% | Reduced |
| Commonwealth Equity Services, LLC | 12,369 | $2.00K | 0.00% | −20.0% | Reduced |
| LPL Financial LLC | 10,023 | $2.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 350 | $0 | 0.00% | −25−6.7% | Reduced |
| Morgan Stanley | 1,502 | $0 | 0.00% | +2+0.1% | Added |
| BlackRock Inc. | 1,197 | $0 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −166,034−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −82,170−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −26,553−100.0% | Sold out |
| Financial Advocates Investment Management | 0 | $0 | 0.00% | −11,472−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |